# Tazemetostat Hydrobromide (Tazverik)

Source: https://ourhealthnetwork.com/drugs/tazemetostat-hydrobromide
Data: FDA Orange Book and OpenFDA, refreshed periodically

## What is Tazemetostat Hydrobromide?

Tazemetostat Hydrobromide (brand name: Tazverik) is an ezh2 inhibitor. It is prescribed to treat sarcoma.

## Brand names

Tazverik

## Indications

Tazemetostat Hydrobromide is primarily prescribed for the treatment of sarcoma.

## Conditions treated

- [Sarcoma](https://ourhealthnetwork.com/conditions/sarcoma)

## Mechanism of action

Tazemetostat is an inhibitor of the methyltransferase, EZH2, and some EZH2 gain-of-function mutations including Y646X, A682G, and A692V. Tazemetostat also inhibited EZH1 with a half-maximal inhibitory concentration (IC 50 ) of 392 nM, approximately 36 times higher than the IC 50 for inhibition of EZH2.

## Drug classification

- Established Pharmacologic Class: EZH2 inhibitors
- Route of administration: ORAL

## Common side effects

constipation, decreased appetite, fatigue, nausea, one patient, pain, vomiting

## Sources and disclaimers

- FDA Orange Book and OpenFDA dataset
- This information is for educational purposes only and does not constitute medical advice. Always consult a healthcare professional before starting, stopping, or changing any medication.

## Related

- [All drugs](https://ourhealthnetwork.com/drugs)
- [Find specialists who prescribe this drug](https://ourhealthnetwork.com/find-doctors)
- [Methodology](https://ourhealthnetwork.com/methodology)